Therapeutic Potential for Cannabis and Cannabinoids

Cannabis has a history of medical use dating back millennia; however, the use of cannabis for medicinal purposes fell out of favor in the middle of the last century. There is currently a renewed interest in the potential medicinal value of this plant, as well as individual compounds produced by Cann...

Полное описание

Сохранить в:
Библиографические подробности
Формат: Online
Язык:английский
Опубликовано: MDPI - Multidisciplinary Digital Publishing Institute 2023
Предметы:
rat
THC
CBD
HIV
n/a
Online-ссылка:ONIX_20230714_9783036575827_25
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!
_version_ 1869521670615597056
collection Directory of Open Access Books
description Cannabis has a history of medical use dating back millennia; however, the use of cannabis for medicinal purposes fell out of favor in the middle of the last century. There is currently a renewed interest in the potential medicinal value of this plant, as well as individual compounds produced by Cannabis (as well as synthetic analogs). Currently, nearly 50 countries permit the medical use of cannabis, and over a dozen other countries have legalized cannabis-based products (CBD, Sativex, Dronabinol, etc.) for medical use. While there exists a plethora of anecdotal reports indicating that cannabis can treat a variety of diseases, there is a limited amount of strong, evidence-based scientific data to support these claims. This Special Edition of Biomedicines, “Therapeutic Potential for Cannabis and Cannabinoids”, was dedicated to providing evidence for the medicinal value of cannabis to treat human illness and disease. Topics included, but were not limited to, preclinical animal models examining the efficacy of cannabis and cannabinoid derivatives on pain, anxiety, cancer, and other diseases; and cell and molecular models of cannabinoid pharmacokinetics, drug–drug interactions, and disease treatment. These studies are of great importance not only for progressing the cannabis field, but also for validating the use of cannabis and cannabinoids as therapeutics.
format Online
id doab-20.500.12854ir-101326
institution Directory of Open Access Books
language eng
publishDate 2023
publishDateRange 2023
publishDateSort 2023
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-1013262024-03-30T23:22:54Z Therapeutic Potential for Cannabis and Cannabinoids Raup-Konsavage, Wesley M. anti-microbial activity anti-biofilm activity Cannabis sativa L. endocannabinoids gut microbiota pathogens phytocannabinoids synovial fibroblast rheumatoid arthritis cannabis tetrahydrocannabinol cytokines calcium PBMC cannabinoid receptors TRPA1 2-hydroxy oleic acid anandamide anti Bcl2 endocannabinoid system membrane lipid therapy neuroblastoma N-arachidonoylethanolamine cortisol chronic pain injury autism spectrum disorder cannabinoids cannabidiol clinical trials randomized controlled sleep child psychiatry developmental disorders rat post-traumatic stress disorder (PTSD) URB597 mGluR5 CB1 receptor fatty acid amide hydrolase (FAAH) β-catenin cannabinoid immune macrophage elderly inflammatory bowel disease D9 tetrahydrocannabinol nitric oxide epilepsy animal model cognitive dysfunction zebrafish ∆9-tetrahydrocannabinol THC CBD prefrontal cortex striatum BDNF aging age-related diseases neuropathic pain anxiety inhalation HRQoL phytochemistry terpenes synergy entourage effect biosynthesis HIV cannabidiol (CBD) tetrahydrocannabinol (THC) chronic liver diseases quality of life pilot clinical trial MMP-2 MMP-9 VSMC H9c2 cells glucose cell proliferation apoptosis cardiovascular disease FAAH inhibitors MGL inhibitors neonatal brain injury hypoxia–ischemia neuroprotection neurogenesis inflammation bile acids transcriptomics estrogen deficiency ovariectomized mice postmenopause gut organoids ghrelin GHSR signaling late adolescence medical cannabis polypharmacy n/a thema EDItEUR::M Medicine and Nursing Cannabis has a history of medical use dating back millennia; however, the use of cannabis for medicinal purposes fell out of favor in the middle of the last century. There is currently a renewed interest in the potential medicinal value of this plant, as well as individual compounds produced by Cannabis (as well as synthetic analogs). Currently, nearly 50 countries permit the medical use of cannabis, and over a dozen other countries have legalized cannabis-based products (CBD, Sativex, Dronabinol, etc.) for medical use. While there exists a plethora of anecdotal reports indicating that cannabis can treat a variety of diseases, there is a limited amount of strong, evidence-based scientific data to support these claims. This Special Edition of Biomedicines, “Therapeutic Potential for Cannabis and Cannabinoids”, was dedicated to providing evidence for the medicinal value of cannabis to treat human illness and disease. Topics included, but were not limited to, preclinical animal models examining the efficacy of cannabis and cannabinoid derivatives on pain, anxiety, cancer, and other diseases; and cell and molecular models of cannabinoid pharmacokinetics, drug–drug interactions, and disease treatment. These studies are of great importance not only for progressing the cannabis field, but also for validating the use of cannabis and cannabinoids as therapeutics. 2023-07-14T14:24:24Z 2023-07-14T14:24:24Z 2023 book ONIX_20230714_9783036575827_25 9783036575827 9783036575834 https://directory.doabooks.org/handle/20.500.12854/101326 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/7420 https://mdpi.com/books/pdfview/book/7420 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-7583-4 10.3390/books978-3-0365-7583-4 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036575827 9783036575834 424 Basel open access
spellingShingle anti-microbial activity
anti-biofilm activity
Cannabis sativa L.
endocannabinoids
gut microbiota
pathogens
phytocannabinoids
synovial fibroblast
rheumatoid arthritis
cannabis
tetrahydrocannabinol
cytokines
calcium
PBMC
cannabinoid receptors
TRPA1
2-hydroxy oleic acid
anandamide
anti Bcl2
endocannabinoid system
membrane lipid therapy
neuroblastoma
N-arachidonoylethanolamine
cortisol
chronic pain
injury
autism spectrum disorder
cannabinoids
cannabidiol
clinical trials
randomized controlled
sleep
child psychiatry
developmental disorders
rat
post-traumatic stress disorder (PTSD)
URB597
mGluR5
CB1 receptor
fatty acid amide hydrolase (FAAH)
β-catenin
cannabinoid
immune
macrophage
elderly
inflammatory bowel disease
D9 tetrahydrocannabinol
nitric oxide
epilepsy
animal model
cognitive dysfunction
zebrafish
∆9-tetrahydrocannabinol
THC
CBD
prefrontal cortex
striatum
BDNF
aging
age-related diseases
neuropathic pain
anxiety
inhalation
HRQoL
phytochemistry
terpenes
synergy
entourage effect
biosynthesis
HIV
cannabidiol (CBD)
tetrahydrocannabinol (THC)
chronic liver diseases
quality of life
pilot clinical trial
MMP-2
MMP-9
VSMC
H9c2 cells
glucose
cell proliferation
apoptosis
cardiovascular disease
FAAH inhibitors
MGL inhibitors
neonatal brain injury
hypoxia–ischemia
neuroprotection
neurogenesis
inflammation
bile acids
transcriptomics
estrogen deficiency
ovariectomized mice
postmenopause
gut organoids
ghrelin
GHSR signaling
late adolescence
medical cannabis
polypharmacy
n/a
thema EDItEUR::M Medicine and Nursing
Therapeutic Potential for Cannabis and Cannabinoids
title Therapeutic Potential for Cannabis and Cannabinoids
title_full Therapeutic Potential for Cannabis and Cannabinoids
title_fullStr Therapeutic Potential for Cannabis and Cannabinoids
title_full_unstemmed Therapeutic Potential for Cannabis and Cannabinoids
title_short Therapeutic Potential for Cannabis and Cannabinoids
title_sort therapeutic potential for cannabis and cannabinoids
topic anti-microbial activity
anti-biofilm activity
Cannabis sativa L.
endocannabinoids
gut microbiota
pathogens
phytocannabinoids
synovial fibroblast
rheumatoid arthritis
cannabis
tetrahydrocannabinol
cytokines
calcium
PBMC
cannabinoid receptors
TRPA1
2-hydroxy oleic acid
anandamide
anti Bcl2
endocannabinoid system
membrane lipid therapy
neuroblastoma
N-arachidonoylethanolamine
cortisol
chronic pain
injury
autism spectrum disorder
cannabinoids
cannabidiol
clinical trials
randomized controlled
sleep
child psychiatry
developmental disorders
rat
post-traumatic stress disorder (PTSD)
URB597
mGluR5
CB1 receptor
fatty acid amide hydrolase (FAAH)
β-catenin
cannabinoid
immune
macrophage
elderly
inflammatory bowel disease
D9 tetrahydrocannabinol
nitric oxide
epilepsy
animal model
cognitive dysfunction
zebrafish
∆9-tetrahydrocannabinol
THC
CBD
prefrontal cortex
striatum
BDNF
aging
age-related diseases
neuropathic pain
anxiety
inhalation
HRQoL
phytochemistry
terpenes
synergy
entourage effect
biosynthesis
HIV
cannabidiol (CBD)
tetrahydrocannabinol (THC)
chronic liver diseases
quality of life
pilot clinical trial
MMP-2
MMP-9
VSMC
H9c2 cells
glucose
cell proliferation
apoptosis
cardiovascular disease
FAAH inhibitors
MGL inhibitors
neonatal brain injury
hypoxia–ischemia
neuroprotection
neurogenesis
inflammation
bile acids
transcriptomics
estrogen deficiency
ovariectomized mice
postmenopause
gut organoids
ghrelin
GHSR signaling
late adolescence
medical cannabis
polypharmacy
n/a
thema EDItEUR::M Medicine and Nursing
topic_facet anti-microbial activity
anti-biofilm activity
Cannabis sativa L.
endocannabinoids
gut microbiota
pathogens
phytocannabinoids
synovial fibroblast
rheumatoid arthritis
cannabis
tetrahydrocannabinol
cytokines
calcium
PBMC
cannabinoid receptors
TRPA1
2-hydroxy oleic acid
anandamide
anti Bcl2
endocannabinoid system
membrane lipid therapy
neuroblastoma
N-arachidonoylethanolamine
cortisol
chronic pain
injury
autism spectrum disorder
cannabinoids
cannabidiol
clinical trials
randomized controlled
sleep
child psychiatry
developmental disorders
rat
post-traumatic stress disorder (PTSD)
URB597
mGluR5
CB1 receptor
fatty acid amide hydrolase (FAAH)
β-catenin
cannabinoid
immune
macrophage
elderly
inflammatory bowel disease
D9 tetrahydrocannabinol
nitric oxide
epilepsy
animal model
cognitive dysfunction
zebrafish
∆9-tetrahydrocannabinol
THC
CBD
prefrontal cortex
striatum
BDNF
aging
age-related diseases
neuropathic pain
anxiety
inhalation
HRQoL
phytochemistry
terpenes
synergy
entourage effect
biosynthesis
HIV
cannabidiol (CBD)
tetrahydrocannabinol (THC)
chronic liver diseases
quality of life
pilot clinical trial
MMP-2
MMP-9
VSMC
H9c2 cells
glucose
cell proliferation
apoptosis
cardiovascular disease
FAAH inhibitors
MGL inhibitors
neonatal brain injury
hypoxia–ischemia
neuroprotection
neurogenesis
inflammation
bile acids
transcriptomics
estrogen deficiency
ovariectomized mice
postmenopause
gut organoids
ghrelin
GHSR signaling
late adolescence
medical cannabis
polypharmacy
n/a
thema EDItEUR::M Medicine and Nursing
url ONIX_20230714_9783036575827_25